Skip to main content

Table 4 Incidence of acute rejection (AR) at 3 and 12 months

From: Lower incidence of CMV infection and acute rejections with valganciclovir prophylaxis in lung transplant recipients

  Oral ganciclovir Valganciclovir p-value
  3 months (n = 37) 3 months (n = 51)  
CAR scorea, median (quartiles)    
3 months 2 (0 – 4) 0 (0 – 2) 0.02
12 months 3 (2 – 6) 1.5 (0 – 3) 0.002
CAR score/TBBb, median (quartiles)    
3 months 0.5 (0 - 1) 0 (0 - 0.5) 0.008
12 months 0.43 (0.2-0.67) 0.14 (0-0.5) 0.001
At least one episode of AR grade ≥ 1, % (n)    
3 months 68% (25/37) 44% (20/45) 0.03
12 months 84% (31/37) 62% (28/45) 0.02
At least one episode of AR grade ≥ 2, % (n)    
3 months 51% (19/37) 29% (13/45) 0.04
12 months 73% (27/37) 49% (22/45) 0.03
At least two episodes of AR grade ≥ 2, % (n)    
3 months 24% (9/37) 13% (6/45) n.s
12 months 41% (15/37) 20% (9/45) 0.04
Number of TBB, median (quartiles)    
3 months 4 (3 – 4) 4 (3 – 4) n.s
12 months 9 (8 – 9) 8 (6 – 8) 0.001
  1. aCumulative acute rejection score (CAR score) varied between 0 and 6 at 3 months and between 0 and 16 at 12 months.
  2. bCumulative acute rejection score (CAR score) divided by the number of evaluable transbronchial biopsies (TBB).